![]() ![]() In addition, the use of CGM in T1DM is continuously expanding due to recent improvements in the accuracy and period of use of the sensor and the expansion of the national reimbursement policy ( 11). In various diabetes guidelines, the use of CGM is suggested as a standard treatment for the management of T1DM ( 9, 10). Studies have demonstrated that the use of CGM improved glycemic control in patients with type 1 diabetes mellitus (T1DM) using daily insulin injection ( 5– 8). The main CGM metrics including time in range (TIR), time below range (TBR), and time above range (TAR) inform more personalized glycemic profiles compared with HbA1c ( 4). Continuous glucose monitoring (CGM) demonstrates a continuous measurement of glucose levels over time and detects glucose variations with CGM metrics ( 3). Hemoglobin A1c (HbA1c) has been the gold standard marker for assessing glycemic status and predicting diabetes complications, but it provides limited information that cannot reflect glycemic variability and the presence of severe hypoglycemia or hyperglycemia ( 1, 2). In the continuous glucose monitoring user group, those who achieved more than 70% of time in range significantly increased from 3 months (37.4%) to 12 months (48.2%) ( P < 0.001).Ĭonclusion: In this longitudinal study of type 1 diabetes mellitus adults, the use of continuous glucose monitoring for 1 year showed a significant reduction in glycated A1c in real-world practice. ![]() A linear mixed model showed an adjusted treatment group difference in mean reduction in glycated A1c of −0.11% (95% confidence interval, −0.16 to −0.06) each three months. Changes in glycated A1c were significant at 3, 6, 9, and 12 months compared with those at baseline in patients using continuous glucose monitoring ( P < 0.001), and the changes differed significantly between the groups ( P < 0.001). Results: The change in glycated A1c from baseline to 12 months was −0.5% ± 1.0% for the continuous glucose monitoring user group ( N = 155, P < 0.001) and −0.01% ± 1.0% for the non-user group ( N = 310, P = 0.816), with a significant difference between the two groups ( P = 0.003). We used the linear mixed models to identify the quantitative reduction in repeated measures of glycated A1c. Individuals with ( N = 155) or without continuous glucose monitoring use ( N = 310) were matched 1:2 by propensity score. Glycated A1c was measured at baseline and 3, 6, 9, and 12 months. Methods: We included type 1 diabetes mellitus adults who were either new continuous glucose monitoring users ( N = 155) or non-users who were under standard care ( N = 384). 2Department of Clinical Research Design and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Republic of KoreaĪim: We explored the effectiveness of continuous glucose monitoring for 1 year on glycated A1c reduction in adults with type 1 diabetes mellitus.1Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.So Hyun Cho 1† Seohyun Kim 2† You-Bin Lee 1 Sang-Man Jin 1 Kyu Yeon Hur 1 Gyuri Kim 1* Jae Hyeon Kim 1,2*
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |